About Cyclenium Pharma
Cyclenium Pharma is a Healthcare company based in Montreal (Canada) founded in 2013 by Mark Peterson, and was acquired by SpiroChem in June 2023. It operates as a canadian, preclinical-stage biopharma developing macrocycle drugs for oncology, infections, and pain. Cyclenium Pharma offers products and services including CMRT Technology and Contract Research Services. Its focus areas include Diversified Pharmaceuticals.
Company details
Cyclenium Pharma was established in 2013 in Montreal, Canada, as a spin-out from Tranzyme Pharma after its merger with Ocera Therapeutics. Focus is placed on preclinical development of macrocycle therapeutics targeting oncology, infections, and pain. Proprietary CMRT technology is utilized for drug discovery, alongside the QUEST Library of macrocyclic compounds. Partnerships have been formed with entities such as Astellas Pharma and Halpogen GmbH to advance operations in the biopharmaceutical sector.
- Headquarters Montreal, Canada
- Founders Mark Peterson
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cyclenium.com
- Social LinkedIn
- Acquired by SpiroChem (Jun 2023)
- Legal Name Cyclenium Pharma
Products & Services of Cyclenium Pharma
Cyclenium Pharma offers a comprehensive portfolio of products and services, including CMRT Technology and Contract Research Services.
Proprietary system for developing small-molecule macrocycles to target difficult diseases
Custom services for pharmaceutical firms to explore macrocycles in drug development
Investors in Cyclenium Pharma
Cyclenium Pharma has secured backing from 1 investor. Prominent investors backing the company include SpiroChem.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry | 2011 | spirochem.com | Zurich, Switzerland |
Investor details for Cyclenium Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cyclenium Pharma
1 people are tracked at Cyclenium Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mark Peterson | Co-Founder & COO | Leadership |
Complete people profiles for Cyclenium Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cyclenium Pharma
2 dated milestones of Cyclenium Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Cyclenium Pharma is founded.
- Exit Acquired by SpiroChem.
Web traffic of Cyclenium Pharma
The website of Cyclenium Pharma (cyclenium.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 1.8% vs previous month
Websites whose visitors overlap most with Cyclenium Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details | |
| bing.com | 100% | 3.5B | #10 | View details |
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Cyclenium Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cyclenium Pharma
Complete news archive for Cyclenium Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyclenium Pharma
Cyclenium Pharma was founded in 2013.
Cyclenium Pharma is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Cyclenium Pharma was established in 2013 in Montreal, Canada, as a spin-out from Tranzyme Pharma after its merger with Ocera Therapeutics. Focus is placed on preclinical development of macrocycle therapeutics targeting oncology, infections, and pain. Proprietary CMRT technology is utilized for drug discovery, alongside the QUEST Library of macrocyclic compounds. Partnerships have been formed with entities such as Astellas Pharma and Halpogen GmbH to advance operations in the biopharmaceutical sector.
Cyclenium Pharma offers CMRT Technology and Contract Research Services.
Cyclenium Pharma has 1 investor. Key investors include SpiroChem.
Cyclenium Pharma operates through Cyclenium Pharma.
Yes. Cyclenium Pharma was acquired by SpiroChem in June 2023.